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Abstract: Breast density, also known as mammographic density, refers to white and bright regions
on a mammogram. Breast density can only be assessed by mammogram and is not related to how
breasts look or feel. Therefore, women will only know their breast density if they are notified by
the radiologist when they have a mammogram. Breast density affects a woman’s breast cancer
risk and the sensitivity of a screening mammogram to detect cancer. Currently, the position of
BreastScreen Australia and the Royal Australian and New Zealand College of Radiologists is to not
notify women if they have dense breasts. However, patient advocacy organisations are lobbying for
policy change. Whether or not to notify women of their breast density is a complex issue and can
be framed within the context of both public health ethics and clinical ethics. Central ethical themes
associated with breast density notification are equitable care, patient autonomy in decision-making,
trust in health professionals, duty of care by the physician, and uncertainties around evidence relating
to measurement and clinical management pathways for women with dense breasts. Legal guidance
on this issue must be gained from broad legal principles found in the law of negligence and the test of
materiality. We conclude a rigid legal framework for breast density notification in Australia would
not be appropriate. Instead, a policy framework should be developed through engagement with all
stakeholders to understand and take account of multiple perspectives and the values at stake.
Keywords: breast density; mammographic density; mammogram; breast cancer screening; clinical
ethics; health policy; duty of care
1. Background
Breast density, also known as mammographic density, refers to white and bright regions on a
mammogram. The whiter the mammogram, the denser the tissue appears. The American College of
Radiology describe four categories of density in the Breast Imaging-Reporting Data Systems (BI-RADS)
Atlas ranging from “Mostly fatty” to “Extremely dense” (Figure 1) [1]. It is estimated that in the
U.S.A., 8% of women aged between 40 and 74 years have “Extremely dense” breasts and 35% have
J. Clin. Med. 2020, 9, 681; doi:10.3390/jcm9030681 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 681 2 of 8
“Heterogeneously dense” breasts [2]. These two density categories are often combined and termed
“dense breasts”. There is no data on the prevalence of density categories in an Australian population;
however, they are likely to be similar to the USA.
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informed by this workshop and through further discussions amongst the inter-disciplinary team of 
authors. In this perspective, we seek to bring together the diverse views held by different 
stakeholders, rather than take a position on one side of the debate or the other, and we have not 
sought to either agree or disagree with current Australian breast density notification policy. Here we 
identify and discuss the ethical and legal issues associated with breast density notification from an 
Australian perspective and highlight the key research required to resolve these issues. 
 
Figure 1. American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) 
classification system of 4 density categories: “Mostly fatty”, “Scattered density”, “Heterogeneously 
dense”, and “Extremely dense”. Reproduced with permission from InforMD (www.informd.org.au). 
2. Main Text 
Government-funded breast cancer screening is a population-based program guided by the 
utilitarian objective of maximising the sum total of welfare. However, as breast cancer screening is 
implemented in a clinic-like situation by clinicians, and women attending the program make 
decisions for their own benefit, issues related to clinical ethics are also at play [17]. What matters in 
public health ethics is somewhat different to what matters in clinical ethics, and these perspectives 
can conflict with each other. Therefore, the framing of this issue within the context of public health 
ethics or clinical ethics is extremely important. The central ethical themes associated with breast 
density notification are equitable care, patient autonomy, trust in the doctor–patient relationship, 
duty of care by the physician, and uncertainties around evidence relating to measurement and clinical 
management pathways for women with dense breasts.  
2.1. Uncertainties in Measurement and Management Pathways 
The reluctance amongst clinicians and health authorities to notify women of their breast density 
is largely related to uncertainties around measurement and clinical management of women with 
dense breasts. The visual assessment of the BI-RADS scale is very subjective, and the assessment of 
density can vary amongst radiologists. For this reason, up to 19% of all women screened could 
potentially be advised differently (dense or non-dense) at the next screen [18], and there is concern 
that this could lead to unnecessary anxiety and an ineffective approach to supplementary screening. 
Automated measurement software programs are now becoming available, and use of quantitative 
measures of breast density, rather than the current qualitative measures, could help address some of 
the clinical concerns. 
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The association between breast cancer risk and density was first described by John Wolfe, who
reported in 1976 that there appeared to be particular parenchymal patterns observed on a mammogram
that were associated with an increased risk of the woman developing breast cancer in the future [3].
However, in the following year, Egan and Mosteller claimed that the finding reported by Wolfe was an
artefact of masking—the breast cancer had already been there, just hidden amongst these parenchymal
patterns [4]. After 40 years of research and debate, it is now widely accepted that breast density is both
an independent risk factor for breast cancer and masks cancer on a mammogram [5–8]. Together, these
two distinct issues result in an increased rate of interval cancers detected in women with dense breasts.
An interval cancer is an invasive breast cancer diagnosed in the interval between the completion of
a negative screening mammogram and the next screening mammogram. In Australia the interval
between screens is 2 years. The interval cancer rate for women with “Extremely dense” breasts is 5.5 per
1000 mammograms, compared to 1.6 per 1000 mammograms for women with “Scattered density” [9].
The current position of BreastScreen Australia and the Royal Australian and New Zealand College
of Radiologists is to not notify women of their breast density [10,11]. However, for over 10 years,
BreastScre n Western Australia has had the policy of notify ng women if they have d nse breasts. The
nformation communicat d by BreastScreen Weste n Aus r lia to women with dense breasts is largely
focussed on reassuring the woman that dense breasts are normal and common, explaining the lowered
sensitivity of the m mogram to detec cancer, and directing women to their GP for a breast check [12].
The incr ased nterval cancer rate that ccurs in women with dense br asts has prompt d a number
of patient advocacy groups in Australia and internationally to call for breast density notifi ation as
par of public breast cancer screening programs. In the United States of America, consumer dvocacy
has led to state, nd now federal, legislation ma dating that all screened women must b inf rmed
of their breast d nsity and the standardisation of breast density reporting laws [13]. The minimum
language must include the message that mammograms are significantly less sensitive in diagnosing
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breast cancer in women with dense breasts, and a reminder to women with dense breasts to consult
their doctor if they have any questions or concerns about their breast density. In Australia, both
Breast Cancer Network Australia and the Pink Hope charity are lobbying for policy change on breast
density [14,15]. In Canada, the patient advocacy group Dense Breasts Canada successfully lobbied
for policy change in British Columbia. Breast density notification to all women attending the British
Columbia Cancer Breast Screening Program became effective on 15 October 2018 [16], with a number of
other Canadian provinces following suit. The screening program in British Columbia does not directly
recommend supplementary ultrasounds for women with dense breasts; however, it has provided
access to government-funded ultrasounds if women wish to pursue this following consultation with
their doctor or nurse practitioner.
To begin to explore the complex ethical considerations associated with breast density notification,
an Australian national stakeholder engagement workshop was conducted, attended by experts in
breast density, breast cancer screening, clinical ethics, and the law, as well as patients and clinicians.
At the workshop, a range of viewpoints were discussed, and it was clear that whether or not to tell
women if they have high breast density, when they have a screening mammogram, is a sensitive
and contentious issue. Different stakeholders hold diverse perspectives; for example, some view the
issue purely in terms of a right to know and argue that women should have the same information
about their own bodies as their doctors have. On the other hand, some caution that knowledge of
breast density can cause harm, including anxiety and an increased rate of false positives in patients
undergoing supplementary screening, without providing a benefit to population-based breast cancer
screening outcomes. The perspectives presented in this manuscript are partially informed by this
workshop and through further discussions amongst the inter-disciplinary team of authors. In this
perspective, we seek to bring together the diverse views held by different stakeholders, rather than take
a position on one side of the debate or the other, and we have not sought to either agree or disagree
with current Australian breast density notification policy. Here we identify and discuss the ethical and
legal issues associated with breast density notification from an Australian perspective and highlight
the key research required to resolve these issues.
2. Main Text
Government-funded breast cancer screening is a population-based program guided by the
utilitarian objective of maximising the sum total of welfare. However, as breast cancer screening is
implemented in a clinic-like situation by clinicians, and women attending the program make decisions
for their own benefit, issues related to clinical ethics are also at play [17]. What matters in public health
ethics is somewhat different to what matters in clinical ethics, and these perspectives can conflict with
each other. Therefore, the framing of this issue within the context of public health ethics or clinical
ethics is extremely important. The central ethical themes associated with breast density notification are
equitable care, patient autonomy, trust in the doctor–patient relationship, duty of care by the physician,
and uncertainties around evidence relating to measurement and clinical management pathways for
women with dense breasts.
2.1. Uncertainties in Measurement and Management Pathways
The reluctance amongst clinicians and health authorities to notify women of their breast density
is largely related to uncertainties around measurement and clinical management of women with
dense breasts. The visual assessment of the BI-RADS scale is very subjective, and the assessment
of density can vary amongst radiologists. For this reason, up to 19% of all women screened could
potentially be advised differently (dense or non-dense) at the next screen [18], and there is concern
that this could lead to unnecessary anxiety and an ineffective approach to supplementary screening.
Automated measurement software programs are now becoming available, and use of quantitative
measures of breast density, rather than the current qualitative measures, could help address some of
the clinical concerns.
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There is also uncertainty in what clinical pathway is appropriate for women with dense breasts.
There are no randomised-controlled trials evaluating the use of supplemental screening in women
with dense breasts that have been run for a sufficient length of time to show a difference in survival.
Supplemental breast ultrasounds in women with dense breasts increases cancer detection by 40% [19],
and a randomised-controlled trial demonstrates addition of supplementary ultrasounds reduces
interval cancer rates and detects cancers of lower grade compared to mammography alone [20].
However, supplementary ultrasounds also increase the rate of recall for further testing (e.g., biopsy) for
women who do not have breast cancer, known as a “false positive” [20]. Tomosynthesis (also known as
three-dimensional mammography) is a screening modality that increases cancer detection compared
to mammography, including in women with dense breasts [21]; however, no randomised-controlled
trials have been conducted long enough to investigate improvements in interval cancer-detection rates
or survival rates [22]. A randomised-controlled trial demonstrated diagnosis of significantly fewer
interval cancers when adjunct magnetic resonance imaging was used for women with extremely dense
breasts compared to mammography alone during a 2-year screening period [23]. Follow-up studies
will likely investigate whether this is associated with improved survival outcomes. Without studies
demonstrating improved survival, the concern is that some of the cancers detected by supplementary
screening modalities could result in diagnosis of cancers that are slow-growing, and these cancers
would never have threatened the patient’s life (known as “overdiagnosis”).
2.2. Equitable Care
BreastScreen Australia is a population-based screening program aimed at reducing breast cancer
mortality. For every 1000 women who are screened two yearly from age 50 to 74, eight breast cancer
deaths are prevented [24]. We pose the question, “Are women with dense breasts getting the same
opportunities for early diagnosis from screening mammography as women with non-dense breasts?”
The answer to this question is unclear. Interval cancer rates are higher in women with dense breasts,
and interval cancers tend to be more advanced at the time of diagnosis than screen-detected cancers [25].
However, women with “Extremely dense” breasts appear to have a similar survival rate compared
to women with breasts of “Scattered density” in the 6 years after a breast cancer diagnosis [26]. In
addition, there is insufficient evidence to determine how women with dense breasts could benefit more
from breast cancer screening. Therefore, it could be argued that even if women with dense breasts are
not receiving the same benefit from screening, any such inequality is not necessarily unjust. Further
research is required to determine the long-term benefits of population-level breast cancer screening in
women with dense breasts.
From the perspective of clinical ethics, individual women who attend breast cancer screening do
so under the belief that it could be of personal benefit to them. Those who then experience interval
cancers associated with dense breasts may feel that this belief was false, and that they did not gain any
benefit from participating in the program. They may feel poorly served, even misled, by the screening
program and that a different pathway ought to have been recommended to them.
Access to supplementary screening for women with dense breasts is not government-funded
in Australia. This raises issues with cost and access. Screening modalities such as ultrasound,
tomosynthesis, and magnetic resonance imaging are an additional expense and are not widely available
in rural areas. However, with the current evidence base, it is not clear whether those who cannot
access and afford supplementary screening are at a disadvantage. Research on the cost-effectiveness of
supplementary screening for women with dense breasts in an Australian setting would be warranted.
2.3. Supporting Patient Autonomy in Decision-Making
“This is my life and my decision” is a strong theme expressed by patients advocating for breast
density notification. The decision to not notify women of their breast density can be viewed as unduly
paternalistic, depriving women of involvement in decision-making. On the other hand, providing
unhelpful information has the potential to undermine a person’s decision-making and cause worry.
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Patients may acknowledge the uncertainties in measurement and management for women with
dense breasts but express a strong desire to be part of decision-making despite this. They may consider
there to be two different issues at play, one being providing the information and the second being what
to do with that information. By contrast, health professionals may view these issues as inter-related.
Patients may argue that although providing information might cause some worry, this should not
automatically be considered harmful.
There are two distinct risks associated with dense breasts, one being the increased risk of breast
cancer and the other being the increased risk that a cancer could be missed on a screening mammogram.
Notifying women of these risks may raise different concerns. BreastScreen Western Australia notifies
women with dense breasts about the reduced sensitivity of cancer detection by letter, but this letter
does not mention the increased risk of breast cancer. There is, however, information about the increased
risk of cancer on the organisation’s website. What information women want to know about their own
breast density, and how best to notify them, remains unclear, and this could be explored through a
deliberative forum.
2.4. Trust in Health Professionals
Women diagnosed with an interval cancer can feel a sense of betrayal when they discover that high
breast density may have been a contributing factor to the cancer not being detected on the screening
mammogram. As the decision to not notify women of their breast density is a decision made by health
authorities, this has the potential to reduce trust in the medical profession. Learning about breast
density and its impact occurs at the very time when patients are most vulnerable. They have just
been diagnosed with breast cancer and need to rely on the expertise of health professionals for their
treatment. So, a loss of trust at this time can be especially damaging.
2.5. Duty of Care by the Physician
In Australia, it is uncommon for there to be laws targeting specific legal conditions or diagnoses,
therefore guidance must be gained from broad legal principles. The question as to whether or not
women should be informed of their breast density has never been addressed by an Australian court
and there are no relevant legislative provisions.
In the absence of specific legislation, the appropriate guidance is to be found in the law of
negligence. Here, the questions of duty of care and standard of care are addressed. With regards to
duty of care, it is well-established that the doctor–patient relationship is one where a duty of care exists.
That duty focusses on the expectation that a doctor will take reasonable care to avoid harm coming
to the patient. What is to be considered here is the question of what constitutes “reasonable care”:
informing the patient, or not informing them.
The test for reasonableness differs depending on the characterisation of the action: diagnosis and
treatment, or provision of pre-treatment advice. If the action is defined as diagnosis and treatment, then
the measure is that of a “responsible body of peers”. Where, however, the action is defined as a failure
to inform, which is the most likely here, then the test is one of materiality: would the information have
been material to that particular patient? Or, to put it another way, would knowledge of breast density
have impacted on the patient’s decision-making processes? The authority for the test of materiality
is the seminal case of Rogers v Whitaker (1992) 175 CLR 479 where it was concluded that “[t]he law
should recognise that a doctor has a duty to warn a patient of a material risk inherent in the proposed
treatment; a risk is material if, in the circumstances of the particular case, a reasonable person in the
patient’s position, if warned of the risk, would be likely to attach significance to it...”.
The legal test is an objective one based on subjective characteristics. Therefore, the question
to be asked would be as follows. Would the reasonable, healthy, asymptomatic woman view this
information as material? In answering this question, the context is always significant. For example, if
the woman who has decided to have the screening test and who is identified as having dense breasts
also has a family history of breast cancer, and expressed concern about it, then the question becomes
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as follows. Would the reasonable, healthy, asymptomatic woman with a family history of breast
cancer and an expressed concern about it view this information as material? It is this lack of certainty
that demonstrates the need to maintain the flexible legal test and to supplement it with clear policy
guidelines. To lock in a specific, narrowly defined test would either create unnecessary obligations or
remove essential protections from some vulnerable women.
3. Conclusions
Breast density notification is an ethically and legally complex issue. It intersects public health
ethics and clinical ethics and brings out different perspectives from different stakeholders. Central
issues include equitable care, patient autonomy, trust, duty of care, and uncertainties around evidence
relating to measurement and clinical management pathways for women with dense breasts. Further
research is required, including analysis of long-term health benefits of screening in women with dense
breasts, an economic evaluation to determine the cost-effectiveness of supplementary screening, and
a deliberative forum to determine what Australian women want to know about their breast density.
Legal guidance on this issue must be gained from broad legal principles found in the law of negligence
and the test of materiality. A rigid legal framework for breast density notification in Australia would
not be appropriate. Instead, a policy framework should be developed through engagement with all
stakeholders to understand and take account of multiple perspectives and the values at stake.
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